Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set-Reference-Cited by-同舟云学术

Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set

Published:2021-10 Issue:5 Volume:51 Page:1139-1145
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Tieu Joanna,Cheah Jonathan TL,Black Rachel J,Christensen Robin,Ghosh Nilasha,Richards Pamela,Robson Joanna,Shea Beverley,Simon Lee S,Singhi Jasvinder A,Tugwell Peter,Boers Maarten,Garibay Marco A Alba,Campochiaro Corrado,Decary Simon,de Witt Maarten,Fernandez Anthony P,Keen Helen I,King Lauren,Hinojosa-Azaola Andrea,Hofstetter Cathie,Gaydukova Inna,George Michael D,Gupta Latika,Lyne Suellen,Makol Ashima,Mukhtyar Chetan,Oo Win Min,Petri Michelle,Pisaniello Huai Leng,Sattui Sebastian E,Russell Oscar,Teixeira Vitor,Toupin-April Karine,Uhunmwangho Courage,Whitstock Margaret,Yip Kevin,Mackie Sarah L,Goodman Susan M,Hill Catherine L

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference15 articles.

1. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis;Hench;Proc Staff Meet Mayo Clin,1949

2. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis;Miloslavsky;Ann Rheum Dis,2017

3. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0;Boers;J Clin Epidemiol,2014

4. Core Domain Set Selection According to OMERACT Filter 2.1: the OMERACT Methodology;Maxwell;J Rheumatol,2019

5. OMERACT Filter 2.1: elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies;Boers;J Rheumatol,2019

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inclusion of harm outcomes in core outcome sets requires careful consideration;Journal of Clinical Epidemiology;2024-10

2. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor SPI-62 prevents morbidity in a mouse model of Cushing’s syndrome;2024-06-01

3. Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases;Seminars in Arthritis and Rheumatism;2024-02

4. Current status and implementation strategies of patient education in core outcome set development;Patient Education and Counseling;2024-01

5. Polymyalgia rheumatica;The Lancet;2023-10